

(1)-

Ram R. Shukla, Ph.D.

ACTION SUMMARY FOR APPLICATION:

S/N: 09 | 043, 665

Date of Action: 4/26/01

Oath/Declaration: OK

Priority: OK/9519776.0 Britain Sept 1995 (Priority Document Present)
371

Drawings: No checked by Draft's man

Action:

1. Claims pending 1-8, 11-21
2. Claims withdrawn 13-21
3. Claims canceled 9, 10
4. Claims under consideration 1-8, 11-12
5. Claims objected - None
6. Claims rejected 1-8, 11-12
7. 101 utility: None
8. 112 first para enablement: 1-8
9. 112 first para written description None
10. 112 2nd para 1-8, 11-12
11. 102 1-4, 11-12
12. 103 1-8, 11-12

Other:

Notes:

Claim 1 reads on both in vivo/in vitro; in vitro not enabled.
no nexus between the preamble and the body of the claim
quiescent cells -? which have never divided
or which went in fluorescence

112 2nd how can growth factor be expressed on the surface of cell line
112 2nd on cell line carry a vector - retroviral packaging cell line/genom of the cells
Claim 5 - viral envelope protein; retroviral envelope protein
112 - surface bound growth factor - no antecedent basis
Claim 7 - antecedent basis for envelope

09 04 3665

371

09071832

3718

I

1-10

Method of harvesting cells (In Vitro)

II

11-21

In Vivo Therapy (human)

→ I 1-12

① 1 1 1 1 1 1 1
2 3 4 5 7 8 9 11 12
6 10


→ II 13-21

New name to Attorney
206-695-1718.

Talked to Downs
He will call Shelton
Buell

John Smith

1/11/01



Method

Class I

In vitro tandem

using Retrovirus vs

Packaging cells for infection

Big issue?

Kathleen William
Mark Fitzgerald.